TW202321303A - 抗pla2r自體抗體媒介膜性腎病變之治療 - Google Patents

抗pla2r自體抗體媒介膜性腎病變之治療 Download PDF

Info

Publication number
TW202321303A
TW202321303A TW111126828A TW111126828A TW202321303A TW 202321303 A TW202321303 A TW 202321303A TW 111126828 A TW111126828 A TW 111126828A TW 111126828 A TW111126828 A TW 111126828A TW 202321303 A TW202321303 A TW 202321303A
Authority
TW
Taiwan
Prior art keywords
antibody
pla2r
day
seq
sequence
Prior art date
Application number
TW111126828A
Other languages
English (en)
Chinese (zh)
Inventor
斯特凡 哈特勒
羅蘭 鮑姆加特納
Original Assignee
德商莫菲西斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商莫菲西斯公司 filed Critical 德商莫菲西斯公司
Publication of TW202321303A publication Critical patent/TW202321303A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW111126828A 2021-07-19 2022-07-18 抗pla2r自體抗體媒介膜性腎病變之治療 TW202321303A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EPEP21186299 2021-07-19
EP21186299 2021-07-19
EP21203870 2021-10-21
EPEP21203870 2021-10-21

Publications (1)

Publication Number Publication Date
TW202321303A true TW202321303A (zh) 2023-06-01

Family

ID=82851755

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111126828A TW202321303A (zh) 2021-07-19 2022-07-18 抗pla2r自體抗體媒介膜性腎病變之治療

Country Status (11)

Country Link
US (1) US20240343822A1 (https=)
EP (1) EP4373574A1 (https=)
JP (1) JP2024525870A (https=)
KR (1) KR20240035816A (https=)
AU (1) AU2022315512A1 (https=)
CA (1) CA3225908A1 (https=)
CL (2) CL2024000146A1 (https=)
IL (1) IL309940A (https=)
MX (1) MX2024000872A (https=)
TW (1) TW202321303A (https=)
WO (1) WO2023001804A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116535510B (zh) * 2023-06-30 2023-11-10 四川省医学科学院·四川省人民医院 一种抗人pla2r的抗体、试剂盒及其应用
WO2025254179A1 (en) * 2024-06-06 2025-12-11 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-ｃｄ３８ 인간 항체 및 그의 용도
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
WO2008037257A2 (en) 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
JP7687956B2 (ja) * 2019-03-15 2025-06-03 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物

Also Published As

Publication number Publication date
JP2024525870A (ja) 2024-07-12
AU2022315512A1 (en) 2024-01-25
KR20240035816A (ko) 2024-03-18
MX2024000872A (es) 2024-02-09
CL2024000146A1 (es) 2024-05-31
IL309940A (en) 2024-03-01
EP4373574A1 (en) 2024-05-29
WO2023001804A1 (en) 2023-01-26
CL2024003440A1 (es) 2025-02-21
CA3225908A1 (en) 2023-01-26
US20240343822A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
US20220162332A1 (en) Activatable anti-pdl1 antibodies, and methods of use thereof
RU2518351C2 (ru) Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
US12435154B2 (en) Bispecific antibodies against CD3 and CD20
JP2022529332A (ja) 抗ＢＣＭＡ抗体及びγ－セクレターゼ阻害剤を使用した併用療法
JP7160533B2 (ja) 多発性骨髄腫（ｍｍ）の処置
TWI838660B (zh) 以抗cd20/抗cd3雙特異性抗體和抗cd79b抗體藥物結合物治療的給藥方法
US20210355229A1 (en) An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
JP2023542291A (ja) びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
TW202321303A (zh) 抗pla2r自體抗體媒介膜性腎病變之治療
TW202235435A (zh) 抗cd38抗體及其用途
US20240368297A1 (en) Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
JP2025537529A (ja) リヒター症候群を治療するためのｃｄ３およびｃｄ２０に対する二重特異性抗体
TW202302642A (zh) 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
WO2021190582A1 (zh) 一种抗ox40抗体药物组合物及其用途
CN118076640A (zh) 抗-pla2r自身抗体介导的膜性肾病的治疗
US20250304689A1 (en) Bispecific antibodies against cd3 and cd20
RU2816994C2 (ru) Антитела к bcma, содержащие только тяжелую цепь
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
HK40123344A (zh) 一种治疗实体瘤的方法
EA045291B1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22
EA052946B1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22
HK40022776B (zh) 仅有重链的抗bcma抗体
CA3064588A1 (en) Activatable anti-pdl1 antibodies, and methods of use thereof
HK1247939A1 (en) Treatment for multiple myeloma (mm)